New drug combo targets brain tumors with genetic flaw

NCT ID NCT04192981

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tests a drug called GDC-0084 given alongside radiation therapy for people whose cancer has spread to the brain and has a specific genetic mutation (PI3K). The main goal is to find the safest dose of the drug and see if the combination helps shrink tumors. Only 21 participants are enrolled, so results are very preliminary.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GDC-0084 (a drug that targets PI3K pathway mutations) combined with whole brain radiation therapy
What this could lead to: If it works, this could point toward a new treatment option for people with brain metastases that have specific genetic mutations.
What could go wrong: This is a very early phase 1 trial with only 21 participants, so it is primarily testing safety and dosing. The combination may not prove effective against the cancer, and side effects could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer Meningeal Carcinomatosis metastatic malignant neoplasm in the brain neoplastic meningitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN METASTASES LEPTOMENINGEAL METASTASIS

Contacts and locations

Locations

BAPTIST ALLIANCE - MCI (Data Collection Only)

Miami, Florida, 33143, United States
Memorial Sloan Kettering Basking Ridge (Consent only)

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen (Consent only)

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center (All protocol activities)

New York, New York, 10065, United States
Memorial Sloan Kettering Commack (Consent only)

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth (All protocol activities)

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (Consent only)

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Westchester (All protocol activities)

Harrison, New York, 10604, United States
University of Washington (Data Collection AND Data Analysis)

Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.